These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 6088712)
1. Chemosensitivity of malignant human brain tumors. Preliminary results. Bogdahn U J Neurooncol; 1983; 1(2):149-66. PubMed ID: 6088712 [TBL] [Abstract][Full Text] [Related]
2. Chromosome number and carmustine sensitivity in human gliomas. Shapiro JR; Pu PY; Mohamed AN; Galicich JH; Ebrahim SA; Shapiro WR Cancer; 1993 Jun; 71(12):4007-21. PubMed ID: 8389658 [TBL] [Abstract][Full Text] [Related]
3. [Drug sensitivity testing of gynecologic tumors using Volm's test and stem cell assay]. Eidtmann H; Jonat W; Maass H Geburtshilfe Frauenheilkd; 1985 Jul; 45(7):477-81. PubMed ID: 4029587 [TBL] [Abstract][Full Text] [Related]
4. Sensitivity of human malignant intracranial tumors against MCNU in vitro in comparison to ACNU and BCNU. Tonn JC; Schönmayr R; Kraemer HP J Neurooncol; 1990 Feb; 8(1):41-5. PubMed ID: 2319289 [TBL] [Abstract][Full Text] [Related]
5. Differential chemosensitivity in human intracerebral gliomas measured by flow cytometric DNA analysis. Iwadate Y; Fujimoto S; Yamaura A Int J Mol Med; 2002 Aug; 10(2):187-92. PubMed ID: 12119557 [TBL] [Abstract][Full Text] [Related]
6. The MTT assay for chemosensitivity testing of human tumors of the central nervous system. Part II: Evaluation of patient- and drug-specific variables. Nikkhah G; Tonn JC; Hoffmann O; Kraemer HP; Darling JL; Schachenmayr W; Schönmayr R J Neurooncol; 1992 May; 13(1):13-24. PubMed ID: 1613536 [TBL] [Abstract][Full Text] [Related]
7. Evidence for a constitutive, verapamil-sensitive, non-P-glycoprotein multidrug resistance phenotype in malignant glioma that is unaltered by radiochemotherapy in vivo. Rieger L; Rieger J; Winter S; Streffer J; Esser P; Dichgans J; Meyermann R; Weller M Acta Neuropathol; 2000 May; 99(5):555-62. PubMed ID: 10805101 [TBL] [Abstract][Full Text] [Related]
8. Variable response to 1,3-bis(2-chloroethyl)-1-nitrosourea of human glioma cells sorted according to DNA content. Kobayashi S; Hoshino T; Dougherty DV; Rosenblum ML J Neurooncol; 1984; 2(1):5-11. PubMed ID: 6088724 [TBL] [Abstract][Full Text] [Related]
9. In vitro analysis of BCNU-sensitivity in human malignant gliomas. II. Cross-resistance studies with cisplatinum and nitrosoureas. Gerosa MA; Rosenblum ML; Stevanoni G; Licata C; Della Corte V; Marcon C; Bricolo A; Tridente G Acta Neurol Scand; 1986 Jan; 73(1):66-70. PubMed ID: 3006422 [TBL] [Abstract][Full Text] [Related]
11. In vitro analysis of BCNU-sensitivity in human malignant gliomas. I. A model study with alkylating, cross-linking and carbamoylating agents in anaplastic astrocytomas of pediatric age. Gerosa MA; Rosenblum ML; Stevanoni G; Tommasi M; Della Corte V; Licata C; Bricolo A; Tridente G Acta Neurol Scand; 1985 Oct; 72(4):414-8. PubMed ID: 3002083 [TBL] [Abstract][Full Text] [Related]
12. Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience. Turner CD; Gururangan S; Eastwood J; Bottom K; Watral M; Beason R; McLendon RE; Friedman AH; Tourt-Uhlig S; Miller LL; Friedman HS Neuro Oncol; 2002 Apr; 4(2):102-8. PubMed ID: 11916501 [TBL] [Abstract][Full Text] [Related]
13. Comparison of in vitro cloning assays for drug sensitivity testing of human brain tumours. Berens ME; Giblin JR; Dougherty DV; Hoifodt HK; Tveit K; Rosenblum ML Br J Neurosurg; 1988; 2(2):227-34. PubMed ID: 3267306 [TBL] [Abstract][Full Text] [Related]
14. Effect of pharmacologic doses of zinc on the therapeutic index of brain tumor chemotherapy with carmustine. Roosen N; Doz F; Yeomans KL; Dougherty DV; Rosenblum ML Cancer Chemother Pharmacol; 1994; 34(5):385-92. PubMed ID: 7520843 [TBL] [Abstract][Full Text] [Related]
15. Short-term culture of pediatric brain tumors. Mackillop WJ; Blundell J; Steele P Childs Nerv Syst; 1985; 1(3):163-8. PubMed ID: 4042106 [TBL] [Abstract][Full Text] [Related]
16. Radiation therapy and hydroxyurea followed by the combination of 6-thioguanine and BCNU for the treatment of primary malignant brain tumors. Prados MD; Larson DA; Lamborn K; McDermott MW; Sneed PK; Wara WM; Chang SM; Mack EE; Krouwer HG; Chandler KL; Warnick RE; Davis RL; Rabbitt JE; Malec M; Levin VA; Gutin PH; Phillips TL; Wilson CB Int J Radiat Oncol Biol Phys; 1998 Jan; 40(1):57-63. PubMed ID: 9422558 [TBL] [Abstract][Full Text] [Related]
17. BCNU (NSC-409962) and procarbazine (NSC-77213) treatment for malignant brain tumors. Levin VA; Crafts DC; Wilson CB; Schultz MJ; Boldrey EB; Enot KJ; Pischer TL; Seager M; Elashoff RM Cancer Treat Rep; 1976 Mar; 60(3):243-9. PubMed ID: 177210 [TBL] [Abstract][Full Text] [Related]
18. Hyperfractionated radiation therapy (HFX RT) followed by multiagent chemotherapy (CHT) in patients with malignant glioma: a phase II study. Jeremic B; Grujicic D; Antunovic V; Djuric L; Stojanovic M; Shibamoto Y Int J Radiat Oncol Biol Phys; 1994 Dec; 30(5):1179-85. PubMed ID: 7961028 [TBL] [Abstract][Full Text] [Related]
19. Vidarabin-monophosphate, BCNU, VM26--an in vitro comparative study of active agents in the treatment of malignant human brain tumours. Bogdahn U; Zapf J; Weber H; Dünisch G; Löbering HG; Martin R; Mertens HG Br J Cancer; 1987 Feb; 55(2):153-8. PubMed ID: 2434122 [TBL] [Abstract][Full Text] [Related]